ENTRY       D11817                      Drug
NAME        Deucravacitinib (JAN/USAN);
            Sotyktu (TN)
PRODUCT     SOTYKTU (E.R. Squibb & Sons)
FORMULA     C20H22N8O3
EXACT_MASS  425.2003
MOL_WEIGHT  422.4405
CLASS       Metabolizing enzyme substrate
             DG01892  CYP1A2 substrate
             DG02919  CYP2B6 substrate
             DG01644  CYP2D6 substrate
             DG02970  CES substrate
              DG03192  CES2 substrate
             DG02924  UGT substrate
              DG03188  UGT1A9 substrate
REMARK      Therapeutic category: 3999
            ATC code: L04AA56
            Product: D11817<JP/US>
EFFICACY    Anti-inflammatory, Tyrosine kinase 2 inhibitor
  DISEASE   Plaque psoriasis [DS:H01656]
COMMENT     Treatment of inflammatory conditions
TARGET      TYK2 [HSA:7297] [KO:K11219]
  PATHWAY   hsa04217(7297)  Necroptosis
            hsa04380(7297)  Osteoclast differentiation
            hsa04621(7297)  NOD-like receptor signaling pathway
            hsa04630(7297)  JAK-STAT signaling pathway
            hsa04658(7297)  Th1 and Th2 cell differentiation
            hsa04659(7297)  Th17 cell differentiation
METABOLISM  Enzyme: CYP1A2 [HSA:1544]; CYP2B6 [HSA:1555], CYP2D6 [HSA:1565], CES2 [HSA:8824], UGT1A9 [HSA:54600]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AA Selective immunosuppressants
                 L04AA56 Deucravacitinib
                  D11817  Deucravacitinib (JAN/USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunological Agents, Other
               Tyrosine Kinase 2 Inhibitor
                Deucravacitinib
                 D11817  Deucravacitinib (JAN/USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D11817  Deucravacitinib (JAN/USAN)
            Drug groups [BR:br08330]
             Metabolizing enzyme substrate
              DG01892  CYP1A2 substrate
               D11817  Deucravacitinib
              DG02919  CYP2B6 substrate
               D11817  Deucravacitinib
              DG01644  CYP2D6 substrate
               D11817  Deucravacitinib
              DG02970  CES substrate
               DG03192  CES2 substrate
                D11817  Deucravacitinib
              DG02924  UGT substrate
               DG03188  UGT1A9 substrate
                D11817  Deucravacitinib
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Non-receptor tyrosine kinases
               JAK family
                TYK2
                 D11817  Deucravacitinib (JAN/USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11817
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11817
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11817
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11817
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D11817
DBLINKS     CAS: 1609392-27-9
            PubChem: 405226682
ATOM        31
            1   N5x N     9.2400  -14.2100
            2   N5x N     9.2400  -15.6100
            3   C8y C    10.4300  -16.3100
            4   C8x C    11.6900  -15.6100
            5   C8y C    11.6900  -14.2100
            6   C8y C    10.4300  -13.5100
            7   C5a C    10.4300  -12.1100
            8   N1b N     9.2400  -11.4100
            9   O5a O    11.6200  -11.4100
            10  C1a C     8.0500  -12.1100
            11  N1b N    12.8800  -13.5100
            12  C8y C    14.0700  -14.2100
            13  N1b N    10.4300  -17.7100
            14  C5a C     9.2400  -18.4100
            15  C1y C     8.0500  -17.7100
            16  O5a O     9.2400  -19.8100
            17  C1x C     6.6500  -17.7100
            18  C1x C     7.3500  -16.5200
            19  C8x C    14.0586  -15.6100
            20  C8x C    15.2653  -16.3198
            21  C8x C    16.5534  -15.6297
            22  C8y C    16.4948  -14.2297
            23  C8y C    15.2881  -13.5199
            24  C8y C    17.7225  -13.4931
            25  O2a O    15.2297  -12.1106
            26  C1a C    16.4339  -11.3471
            27  N5x N    18.8626  -14.3047
            28  N4y N    19.9828  -13.4734
            29  C8x C    19.5384  -12.1511
            30  N5x N    18.1435  -12.1652
            31  C1a C    21.2792  -13.8795
BOND        34
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     6   7 1
            8     7   8 1
            9     7   9 2
            10    8  10 1
            11    5  11 1
            12   11  12 1
            13    3  13 1
            14   13  14 1
            15   14  15 1
            16   14  16 2
            17   17  15 1
            18   15  18 1
            19   18  17 1
            20   12  19 2
            21   19  20 1
            22   20  21 2
            23   21  22 1
            24   22  23 2
            25   12  23 1
            26   22  24 1
            27   23  25 1
            28   25  26 1
            29   24  27 2
            30   27  28 1
            31   28  29 1
            32   29  30 2
            33   24  30 1
            34   28  31 1
///
